Shalabh Gupta
An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion, which will decide whether or not to retain it. |
 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (January 2025) |
Shalabh Gupta, M.D., is an Indian-born American physician, entrepreneur, and biotechnology executive. He is the founder and CEO of Unicycive Therapeutics, a clinical-stage biotechnology company focused on developing therapies for rare diseases. He is the first person to simultaneously work as an analyst on Wall Street and as a practicing physician.
Early life and education
[edit]Shalabh Gupta was born in Fatehapur, Uttar Pradesh, and raised in Kanpur, India.[1] Inspired by his father's medical practice, Gupta pursued a career in medicine.[2] He attended medical school at the NYU Grossman School of Medicine, where he specialized in internal medicine, physical medicine and rehabilitation, and cardiology.[1] Later, he earned a master's degree in public administration from the NYU Robert F. Wagner Graduate School of Public Service.[3]
Gupta has been vocal about his frustrations with the inefficiencies of the American healthcare system, which influenced his decision to pursue medicine and entrepreneurship.[2] As a medical resident, he recalls being the sole physician responsible for up to 50 hospital patients during certain shifts, an experience that underscored the challenges of the healthcare industry.[4]
Career
[edit]After completing medical school, Gupta went to work on Wall Street, where he became known as the first analyst to work in finance while simultaneously practicing medicine on weekends and holidays.[1] He later joined Genentech as a commercial strategist, a role he describes as his favorite job.[3]
In 2016, Gupta founded Unicycive Therapeutics, his third entrepreneurial venture.[4] Unicycive specializes in rare diseases, an area he chose because such conditions are often overlooked by large pharmaceutical companies due to their limited profitability.[1][2] Gupta wanted to develop innovative therapies for underserved populations. One of the company's lead drugs, Oxylanthanum Carbonate (OLC), is an investigational phosphate-binding agent aimed at treating hyperphosphatemia in dialysis patients with chronic kidney disease. Gupta identified the drug's potential when it was shelved by a previous company focusing on oncology, and Unicycive bought it.[2][4]
Gupta has taken a unique approach at Unicycive by identifying and revitalizing shelved drugs with untapped potential. In 2018, he acquired two products for the company and successfully took it public without venture capital funding.[4] His strategy emphasizes addressing the unmet needs of rare disease patients and advancing nephrology research.[2]
In addition to his role at Unicycive, Gupta serves as an advisor to the Stanford University Spark Program and UCSF Innovation Ventures.[5]
Personal life
[edit]Shalabh Gupta draws inspiration from gardening, books, and his family. He enjoys reading non-fiction biographies, playing the guitar with his son, and traveling, particularly to Tuscany.[1] One of his favorite books is Shoe Dog by Phil Knight. He has cited Warren Buffett as a personal inspiration, particularly for his investing philosophy.[4]
References
[edit]- ^ a b c d e "Shalabh Gupta, MD: The physician entrepreneur leading the charge in biotech innovation". Business Daily. 2024-09-17. Retrieved 2024-12-31.
- ^ a b c d e "Blazing Trails In Biotech". Mifeed. 2024-12-09. Retrieved 2024-12-31.
- ^ a b "Management Team". Unicycive Therapeutics, Inc. Retrieved 2024-12-31.
- ^ a b c d e "A sit-down with Unicycive's Shalabh Gupta". LA Harbor News. 2024-08-11. Retrieved 2024-12-31.
- ^ "Doctor to IPO: How Shalabh Gupta Became a Biotech Entrepreneur". Founders Network. Retrieved 2024-12-31.
External links
[edit]- Profile on Bloomberg.com
- Shalabh Gupta on Twitter
- The HARD Questions - One-on-one with Our CEO and Board Member on YouTube